Copyrights Licenses

Notice of Intent to Sole Source: Copyright Clearance Center, Inc.

The United States Food and Drug Administration (FDA) hereby issues this notice of intent to sole source. The FDA intends to award a firm fixed-price contract to Copyright Clearance Center, Inc. of 222 Rosewood Dr, Fl 10 Danvers, MA 01923 USA in accordance with FAR part 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The proposed NAICS code for these services is 533110 - Lessors of nonfinancial intangible assets (except copyrighted works).
The purpose of this acquisition is to provide Annual Copyright License (ACL) and Motion Picture License (MPL) with automatic crediting and compensation of the creator of the copyrighted published materials to allow the FDA to legally copy, share, and internally store copyrighted print and digital media material at no additional cost. The period of performance shall be 12 months, from July 2018 to July, 2019.

Copyright Clearance Center, Inc. is the sole provider for this service as they are the only vendor shown to provide copyright clearance services for published material distribution purposes. CCC is also the only operational database service that compensates publishers and creators on the back-end before user access.

This notice is not a request for competitive proposals. All responsible sources may submit a capability statement, providing sufficient information for the government to evaluate that the respondent has the capabilities to provide these services. Capability statements must be received by the response date and time of this notice. Submissions will be reviewed to determine if they can meet the requirement and all submissions received by the closing date of the notice will be considered by the Government. A determination by the Government to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.
It is anticipated that an award will be issued to Copyright Clearance Center, Inc. within approximately fifteen (15) days after the date of this notice unless the Government determines that any other organization has the capacity to meet this requirement.

Response Date: 4:00 p.m. ET on March 30, 2017. Please email responses to Aimee Swann at aimee.swann@fda.hhs.gov.